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SI Methods 
BIOMOL Green ATPase assay — Purified p97 (25 µL of 50 µM; final concentration in the 
reaction was 25 nM monomer concentration) was diluted in 30 mL of assay buffer [10 mL of 5 
x assay buffer A (1 x = 50 mM Tris pH 7.4, 20 mM MgCl2, 1 mM EDTA,) mixed with 20 mL 
water and 50 µL 0.5 M TCEP, 50 µL 10% Triton] to make the enzyme solution. 30 µL of the 
enzyme solution was dispensed into each well of a 96-well plate and 10 µL of p97 cofactor (0 
– 4000 nM) was added into each well. The ATPase assay was carried out by adding 10 µL of 
1000 µM or 4000 µM ATP (pH 7.5) to each well and incubating the reaction at room 
temperature for 35 min. Reactions were stopped by adding 50 µL of BIOMOL Green reagent 
(Enzo Life Sciences). Absorbance at 635 nm was measured after 4 min. Eight final ATP 
concentrations were used to determine steady-state kinetic constants. For mutants, reaction 
times were adjusted according to specific activities in order to obtain acceptable absorbance 
readings. Michaelis-Menten constants were calculated from 8 replicates by fitting data to 
Equation 1 using GraphPad Prism 6.0.  
ν = Vmax*[ATP]/(Km + [ATP])                              (1) 
 
In vitro His pull-down assays —12 µM His-tagged p97 was mixed with 30 µM p47, p37, or 
p47 variants in 100 µL buffer [20 mM HEPES, pH 7.4, 250 mM KCl, 1mM MgCl2, 200 µM 
ATP, 0.01% Triton, 10 µL MagneHis™ Ni-Particles (Promega, V8560)] at room temperature 
for 30 min. Unbound supernatant was removed, and Ni-Particles were washed with 500 µL 
washing buffer (50 mM HEPES, pH 7.4, 150 mM KCl, 5 mM MgCl2, 20 mM imidazole) 3 
times. Bound proteins were eluted by adding 100 µL 1x Laemmli Sample Buffer (Bio-Rad) 
and heated to 90oC for 5 min. Samples were separated on 4-20% Tris-Glycine Gel (Bio-Rad) 
and stained with Coomassie blue (Thermo Scientific Imperial Protein Stain).  
Microscale Thermophoresis (MST) — MST was carried out at 25 °C on a Monolith 
NT.115pico instrument (Nano-Temper Technologies). Full-length p37 and p47 were 
exchanged to 1x assay Buffer A containing TCEP and Pluronic acid (50 mM Tris pH 7.4, 20 
mM MgCl2, 1 mM EDTA, 0.5 mM TCEP, 0.05% Pluronic acid) and labeled with NanoTemper 
647 cysteine-reactive red dye per the manufacturer’s instructions. In this assay, unlabeled 
p37 or p47 was titrated against 400 pM of NT-647 labeled p37 or p47 in two fold steps from 
250 nM to 61 pM. Assays were performed in hydrophilic capillaries in two separate 
experiments. 
Surface plasmon resonance (SPR) — Binding affinities for p37 and p47 cofactors to p97 
proteins were measured on a Biacore 4000 instrument. NeutrAvidin-coated sensor chips 
were prepared as described (1) with the following exceptions: 60 mM N-hydroxysuccinimide 
and 240 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide was injected for 4 min, followed 
by a 2 min injection of 0.25 µg/mL NeutrAvidin. p97 proteins were immobilized in 10 mM 
HEPES, pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 0.05% Tween 20 to 500-600 RU by injecting 
4-6 µg/mL protein for 2 min.  
Binding of cofactor proteins was measured in 25 mM Tris, pH 7.5, 150 mM NaCl, 10 mM 
MgCl2, 0.5 mM TCEP, 0.05% Tween 20 and 0.1% Prionex (Calbiochem) at 20 °C. 
Sensorgrams were reduced, double-referenced, and fit to a 1:1 kinetic interaction model 
(p37) or to an equilibrium binding model for a 1:1 interaction (F253S p47) or a 2:1 interaction 
(WT p47, Δ69-92 p47, Δ83-92 p47 and 83-88 (DE5to NQ5) p47) in Scrubber 2 (BioLogic 
Software).  
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p97-mediated post-mitotic Golgi reassembly assay — The assay was carried out in vitro with 
purified Golgi membranes, p97, and its cofactors (2,3). Briefly, purified rat liver Golgi stacks 
were treated with mitotic cytosol, and the resulting membrane fragments were incubated with 
indicated amounts of purified p97/p47, p97/Δ69-92 p47, or p97/p37 proteins for reassembly. 
Membranes were processed for EM, and the results were quantified to estimate the activity of 
membrane fusion to form cisternal membranes. Mitotic Golgi fragments were normalized to 
0%. Reassembly with WT p97 (167 nM hexamer) and p47 (167 nM trimer) was normalized to 
100%. The results represent the mean of at least ten EM images ± SEM. 
Western blot analysis — Human osteosarcoma U2OS cells were maintained in DMEM 
supplemented with penicillin/streptomycin and 10% fetal bovine serum.  Cells were 80% 
confluent at the time of transfection with Flag-p47 plasmid. Transfections were performed 
with BioT reagent (Bioland Scientific LLC). Cells were lysed with Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Scientific). The sample (25 µg) was loaded on a 4-20% gel for 
SDS-PAGE (Bio-Rad). Proteins were transferred to nitrocellulose membranes using the 
Trans-Blot Turbo system (Bio-Rad). Antibodies used include p97 (MA3-004, Thermo 
Scientific), Flag (F3165, Sigma-Aldrich), p62 (M162-3, MBL International Corporation), p47 
(15620-1-AP, Proteintech Group Inc.), LC3 (PM036, MBL International Corporation), and 
GAPDH  (2118, Cell Signaling Technology). 
Determining IC50 values of p97 inhibitors in ATPase assays — The detailed method was 
described previously (1,4). Inhibition of human p97 (25 nM monomer) was carried out in 
assay buffer (50 mM Tris pH 7.4, 20 mM MgCl2, 1 mM EDTA, 0.5 mM TCEP) containing 
0.01% Triton X-100 and 200 µM ATP. The 8-dose titration was performed at 40, 13.3, 4.4, 
1.48, 0.49, 0.16, 0.05, and 0 µM. ATPase activity was determined through the addition of 
Biomol Green Reagent (Enzo Life Sciences). p47 was added to a final concentration of 400 
nM. NMS-873 was purchased from Xcess Biosciences Inc. 
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Supplemental Tables. 
Table S1. Plasmids used in this study 
Plasmid 
Number Plasmid name Vector 
Source and 
Reference 
TCB-197/ 
SLB-001 Human p97 pET15_T pET15b_TEV linker Chou, 2014* 
TCB-213 E305Q human p97 pET15_T pET15b_TEV linker Chou, 2014* 
TCB-221 E578Q human p97 pET15_T pET15b_TEV linker Chou, 2014* 
TCB-210 R155H human p97 pET15_T pET15b_TEV linker This study 
TCB-366 L198W human p97 pET15_T pET15b_TEV linker This study 
TCB-211 A232E human p97 pET15_T pET15b_TEV linker This study 
TCB-256 A232E, E305Q human p97 pET15_T pET15b_TEV linker This study 
TCB-249 A232E, E578Q human p97 pET15_T pET15b_TEV linker This study 
TCB-403 R155H, E305Q human p97 pET15_T pET15b_TEV linker This study 
TCB-404 R155H, E578Q human p97 pET15_T pET15b_TEV linker This study 
TCB-328 Rat p47 pET15_T pET15b_TEV linker Chou, 2014* 
TCB-424 Δ69-92 rat p47 pET15_T pET15b_TEV linker This study 
TCB-431 Δ83-90 rat p47 pET15_T pET15b_TEV linker This study 
TCB-432 83-88 (DE5to NQ5) rat p47 pET15_T pET15b_TEV linker This study 
TCB-377 F253S rat p47 pET15_T pET15b_TEV linker This study 
TCB-327 Human p37 pET15_T pET15b_TEV linker This study 
TCB-451 Flag-rat p47 pCMV5B Alexandru, 2008** 
SLB-024 C-AviTag human p97 pET15_T pET15b_TEV linker Chou, 2014* 
SLB-049 R155H C-AviTag human p97 pET15_T pET15b_TEV linker This study 
SLB-055 A232E C-AviTag human p97 pET15_T pET15b_TEV linker This study 
--- pBirAcm pACYC184 Avidity 
 
*Chou, T. F., Bulfer, S. L., Weihl, C. C., Li, K., Lis, L. G., Walters, M. A., Schoenen, F. J., Lin, H. J., 
Deshaies, R. J., and Arkin, M. R. (2014) Specific inhibition of p97/VCP ATPase and kinetic analysis 
demonstrate interaction between D1 and D2 ATPase domains. J. Mol. Biol. 426, 2886-2899. 
** Alexandru, G., Graumann, J, Smith, G. T., Kolawa, N. J., Fang, R., and Deshaies, R. J. (2008) 
UBXD7 binds multiple ubiquitin ligases and implicates p97 kin HIF1alpha turnover. Cell 134, 804-816. 
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Table S2. Gel filtration to determine the oligomeric states of p37, p47, and p47 variants. 
Gel filtration was carried out with Superdex 75 10/300 GL (GE Healthcare). The column was 
calibrated with molecular weight (MW) standards kit (Sigma). The standards are Blue Dextran [MW is 
2000 kDa; used to determine the void volume (Vo) of the column], β-amylase (200 kDa), alcohol 
dehydrogenase (150 kDa), bovine serum albumin (66 kDa), and carbonic anhydrase (29 kDa). The 
linear molecular weight calibration plotted Ve/Vo versus Log MW (see standard curve), where Ve is 
the elution volume of the MW standard and Vo is the void volume. To determine the apparent 
molecular weight of p37, p47, or p47 variants, we injected 100 µL of 20 µM proteins, determined their 
elution volumes (Ve), and then calculated apparent molecular weights using the equation obtained 
from the standard curve. The calculated MW was divided by the monomer MW to calculate the 
oligomeric state. 
Molecular Weight 
Standard 
Molecular 
Weight (kDa) 
Elution 
Volume (mL) Ve/Vo Log MW 
Carbonic Anhydrase 29 12.15 1.421 1.462 
Bovine Serum Albumin 66 10.2 1.192 1.819 
Alcohol Dehydrogenase 150 9.3 1.087 2.176 
β-Amylase 200 8.95 1.046 2.301 
Blue Dextran 2000 8.55 1 	  
 
             
Proteins Ve (mL) Ve/Vo 
Log 
(calculated 
MW) 
Calculat
ed MW 
(kDa) 
Monomer 
MW (kDa) Oligomer* 
WT p47 9.8 1.15 2.03 107.3 40.87 2.6 
WT p37 9.9 1.16 2.00 101.0 37.27 2.7 
83-88 (DE5 to NQ5) 
p47 9.8 1.15 2.03 107.3 40.87 2.6 
Δ83-90 p47 9.9 1.16 2.00 101.0 39.88 2.5 
47-371 p47 
(ΔUBA p47) 9.9 1.16 2.00 101.0 36.18 2.8 
Δ69-92 p47 10.1 1.18 1.95 89.7 37.97 2.4 
* The calculated MW was divided by the monomer MW to calculate the oligomer number. 
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Table S3. Binding affinities for p97 cofactors to WT p97 and disease mutants R155H 
and A232E, measured by SPR. 
 WT p97 R155H p97 A232E p97 
 KD1 µM KD2 µM KD1 µM KD2 µM KD1 µM KD2 µM 
WT p371 0.016  0.015  0.015  
WT p472  0.026 1.4 0.021 0.098 0.019 0.70 
F253S p473 5.6  2.93  2.36  
Δ69-92 p472 0.023 1.5 0.018 1.1 0.016 0.71 
Δ83-90 p472 0.030 1.2 0.023 1.0 0.021 0.91 
83-88 (DE5 to NQ5) p472 0.032 1.4 0.025 0.87 0.022 0.70 
1KD values determined using a one-site kinetic fit. 
2KD values determined using a two-site equilibrium fit. 
3KD values determined using a one-site equilibrium fit. 
 
 
	   7	  
Supplemental Figure 
Figure S1 
A                                                                          B 
   
 
C                                                                   D 
   
E 
 
F                                                                  G 
    
	   8	  
 
H                                                                                     I 
  
J                                                                       K 
           
 
Figure S1. Regulation of p97 ATPase activity by p37 and p47. (A) Diagram showing the domain 
representation of human p97 and the mutations analyzed in this study. (B) Differences in N-domain 
conformations between WT and p97 disease mutants. (C) Normalized WT ATPase activities (4.17 nM 
hexamer) in the presence of increasing amounts of p47 (0 to 800 nM) for 200 µM versus 800 µM ATP. 
Error bars indicate ± SD (n=6). (D) Normalized WT ATPase activities (4.17 nM versus 20.8 nM 
hexamer) in the presence of increasing amounts of p47 (0 to 800 nM) for 800 µM ATP. Error bars 
indicate ± SD (n=6). (E) Normalized ATPase activities of WT, R155H, L198W, and A232E p97 (4.17 
nM hexamer) in the presence of increasing amounts of p47 (0 to 800 nM) with 800 µM ATP. Error 
bars indicate ± SD (n=12, excluding L198W, where n=6). (F) Normalized WT ATPase activities (4.17 
nM hexamer) in the presence of increasing amounts of p37 (0 to 800 nM) for 200 µM versus 800 µM 
ATP. Error bars indicate ± SD (n=6). (G) Normalized ATPase activities of WT, R155H, L198W, and 
A232E p97 (4.17nM hexamer) in the presence of increasing amounts of p37 (0 to 800 nM) with 800 
µM ATP. Error bars indicate ± SD (n=6). (H) ATPase activities of WT, D1-E305Q, R155H, and the 
R155H, D1-E305Q double mutant were measured in the presence of p47 (0 to 800 nM) with 200 µM 
ATP. Error bars indicate ± SD (n=12, excluding double mutant R155H,E305Q, where n=6). (I) 
Normalized ATPase activities of WT, D1-E305Q, A232E, and the A232E, D1-E305Q double mutant 
were measured in the presence of p47 (0 to 800 nM). Error bars indicate ± SD (n=12). (J) ATPase 
activities of D1-E305Q and D2-E578Q were measured in the presence of p37 with 200 µM ATP. Error 
bars indicate ± SD (n=6). (K) Normalized ATPase activities of WT (4.17 nM hexamer) in the presence 
of increasing amounts of WT p47 and ΔUBA p47 (0 to 800 nM) with 200 µM ATP. The activity of each 
p97 protein was normalized to its basal activity in the absence of cofactor. Blue lettering indicates the 
active ATPase domain in each protein, and green lettering indicates the Walker B mutant. Error bars 
indicate ± SD (n=12 for WT p47, n=6 for ΔUBA p47). 
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Figure S2 
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Figure S2. Gel filtration and microscale thermophoresis analysis. Gel filtration was used to 
determine the stability of the p97-p47 complex for both WT and R155H p97. 1.67 µM p97 hexamer 
was mixed with 80 µM p47 for 10 min and fractionated in HEPES buffer (20 mM HEPES, 150 mM 
KCl, 1 mM MgCl2, 5% glycerol, pH 7.4) with a gel filtration column (Superdex 20010/300 GL, GE 
Healthcare). (A) Western blot for Fractions 17 to 23. (B) Western blot for Fractions 24 to 30. 
Microscale thermophoresis (MST) analysis was used to determine the equilibrium binding constant 
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(KD) for trimer formation in solution for both (C) p37 and (D) p47. Unlabeled p97 cofactor was titrated 
against 400 pM of NT-647 labeled cofactor in two fold steps from 500,000 pM to 15 pM. Assays were 
performed in hydrophilic capillaries using a Monolith NT.115pico instrument. 
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Figure S3 
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Figure S3. WT p97 and disease mutants display similar binding to p47, and removal of p47 
amino acids 69-92 does not affect p47-p97 interactions. (A) p47 and p37 sequence alignment. 
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Amino acid sequences were aligned using CLC Sequence Viewer 6 (CLC Bio). The alignment 
showed that p47 amino acid residues 69-92 (in red) are completely absent in p37. (B) and (C) An in 
vitro His pull-down assay was carried out by mixing 12 µM His-tagged p97 with 30 µM p47, p37, 
F253S p47, or Δ69-92 p47 at room temperature for 30 min. Unbound supernatant was removed, and 
Ni-Particles were washed with 500 µL washing buffer (50 mM HEPES, pH 7.4, 150 mM KCl, 5 mM 
MgCl2, 20 mM imidazole) 3 times. Bound proteins were eluted by adding 100 µL 1x Laemmli Sample 
Buffer (Bio-Rad) and heated at 90oC for 5 min. Samples were separated on 4-20% Tris-Glycine Gels 
(Bio-Rad) and stained with Coomassie blue (Thermo Scientific Imperial Protein Stain). (B) 
Comparison of WT and A232E p97. (C) Comparison of WT and R155H p97. 
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Figure S4 
	  
Figure S4. SPR sensorgrams for p37 and p47 binding to WT p97 and disease mutants R155H 
and A232E. (A) Binding of WT p37 (67 pM-102.4 nM; 2.5 fold dilutions) to immobilized p97 fit to a 1:1 
kinetic model (orange line).  (B) Binding of WT p47 (419 pM-4 µM; 2.5 fold dilutions) to p97 fit to a 
two-site equilibrium-binding model (inset). (C) Binding of F253S p47 (2.6 nM-25 µM; 2.5 fold dilutions) 
to p97 fit to a one-site equilibrium-binding model (inset).  (D-F) Binding of Δ69-92 p47 (D) Δ83-92 p47  
(E) and 83-88 DE5 to NQ5 (F) (419 pM-4 µM; 2.5 fold dilutions) to p97 fit to a two-site equilibrium-
binding model (insets).  
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Figure S5 
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Figure S5. The R155H disease mutant displays elevated activity and reduced responses to the 
activating effect of p37, as shown by a p97-mediated post-mitotic Golgi reassembly assay. The 
assay was carried out in vitro with p97 cofactors. Purified rat liver Golgi stacks were treated with 
mitotic cytosol, and the resulting membrane fragments were re-isolated by centrifugation and further 
incubated with purified p97 and either p47, Δ69-92 p47, or p37. Membranes were processed for EM, 
and the results were quantified to estimate the percentage of cisternal membranes fro the activity of 
cisternal membrane regrowth. Mitotic Golgi fragments were normalized to 0%. Reassembly with p97 
(167 nM hexamer) and p47 (167 nM trimer) was normalized to 100%. The results represent the mean 
of at least ten EM images ± SEM. (A) p97-mediated post-mitotic Golgi reassembly assays. Column 1: 
Control (mitotic Golgi fragments), 2: WT p97 alone (167 nM hexamer), 3: R155H p97 alone (167 nM 
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hexamer), 4: WT p97 (167 nM hexamer) with 167 nM p37 trimer, 5: WT p97 (167 nM) with 1336 nM 
p37 trimer, 6: R155H p97 (167 nM) with 167 nM p37 trimer, 7: R155H p97 (167 nM) with 1336 nM p37 
trimer. (B) Column 1: Control, 2: WT p97 alone (167 nM hexamer), 3: WT p97 (167 nM hexamer) with 
167 nM p47 trimer, 4: WT p97 (167 nM hexamer) with 1336 nM p47 trimer, 5: WT p97 (167 nM 
hexamer) with 167 nM Δ69-92 p47 trimer, 6: WT p97 (167 nM) with 1336nM Δ69-92 p47 trimer, 7: WT 
p97 (167 nM) with 167 nM p37, 8: WT p97 (167 nM) with 1336 nM p37. 
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Figure S6 
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Figure S6. p47 improves p97/VCP disease associated autophagy impairment. (A) Western blot 
assays to evaluate the effect of p47 in the autophagy pathway. U2OS cells were transiently 
transfected with Flag-p47 plasmid for 48 h to overexpress Flag-p47 (lanes 2 and 4). After 44 h of 
transfection, U2OS cells were treated with 200 nM Bafilomycin A for 4 h, to perform an “autophagic 
flux” assay (lane 3 and 4). GAPDH served as a loading control.  (B) Western blot assays to evaluate 
the effects of p47 on the disease mutant in the autophagy pathway. U2OS cells stably expressing WT, 
L198W, or A232E p97 proteins were used to determine the effect of p47 on the autophagy pathway. 
Cells were transiently transfected with Flag-p47 plasmid (2.5 or 5 µg) for 30 h. GAPDH served as a 
loading control. 
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Figure S7 
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Figure S7. IC50 values of p97 inhibitors against WT p97, the p97-p47 complex, R155H p97, and 
the R155H p97-p47 complex. (A) Chemical structures of DBeQ, ML240, ML241, and NMS-873. (B) 
IC50 values of DBeQ. (C) IC50 values of ML240. (D) IC50 values of ML241. (E) IC50 values of NMS-873. 
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Figure S8 
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Figure S8. Cofactor-induced changes in p97 ATPase activity. Diagram showing the domain 
representation of human p97 and p37, or Δ69-92 p47 cofactors. Illustrations depict changes in p97 
ATPase activity of WT and disease mutants caused by the presence of (A) p37, or (B) Δ69-92 p47. 
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